UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 26, 2002
BIOJECT MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
Oregon
(State or other jurisdiction
of incorporation) | | 0-15360
(Commission
File Number) | | 93-1099680
(IRS Employer
Identification No.) |
| | | |
7620 S.W. Bridgeport Road, Portland, OR
(Address of principal executive offices) | | 97224
(Zip Code) |
Registrant’s telephone number, including area code:(503) 639-7221
No Change
(Former name or former address, if changed since last report)
TABLE OF CONTENTS
Item 5. Other Events
Attached to this Form 8-K as Exhibit 99.1 and incorporated into this Form 8-K by reference is the company’s press release dated February 26, 2002 announcing that Amgen Inc. has given notice to the company of its election not to pursue further development of Iject and B2000 devices.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
| | |
| | 99.1 Press release dated February 26, 2002. |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 27, 2002.
| | | |
| | BIOJECT MEDICAL TECHNOLOGIES, INC.
|
|
| | By: | /s/ Christine M. Farrell |
| |
|
| | Christine M. Farrell
Controller and Secretary |
2
EXHIBIT INDEX
| | | | | | | |
| Exhibit | | Description | | | | |
| |
| | | | |
| 99.1 | | Press release dated February 26, 2002. |
